IMVT
Immunovant, Inc.
Biotechnology · Healthcare · United States
29.17
close · 2026-10-30
value
85
cheaper than peers85
quality
75
stronger fundamentals75
ranked against
Biotechnology (pre-revenue)
value
quality
109 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -5.9% | 84 |
| earnings yield, 2 years ago | -6.4% | 83 |
| cash flow yield, 2 years ago | -3.6% | 76 |
| cash flow yield, 3 years ago | -3.1% | 76 |
| earnings yield, 1 year ago | -9.4% | 74 |
| earnings yield, latest year | -9.5% | 74 |
| cash flow yield, latest year | -6.8% | 72 |
| cash flow yield, 1 year ago | -6.3% | 70 |
| price to book | 8.18× | 18 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.0% | 99 |
| operating margin | 0.0% | 50 |
| return on equity | -80.1% | 38 |
3 of 4 measures available
Facts
| market cap | $6B |
| free cash flow | -$234.0M |
| employees | 315 |
| first trade | 2019-06-21 |
| next earnings | 2026-11-09 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2026 | 2025 | 2024 | 2023 |
| diluted eps | -2.77 | -2.73 | -1.88 | -1.71 |
| free cash flow | -$407.3M | -$376.6M | -$214.6M | -$188.4M |
| net income | -$505.6M | -$413.8M | -$259.3M | -$211.0M |
| revenue | $0 | $0 | $0 | $0 |
| unusual items | $0 | $0 | -$12.5M | -$10.0M |